Novo Nordisk, the Danish company that had spent decades making insulin, watched the trajectory and built its own longer-acting GLP-1 analogues: liraglutide, sold as Victoza for diabetes in 2010 and Saxenda for weight loss in 2014, then semaglutide, approved as Ozempic in 2017
Persistent dryness may signal hydration issues that need medical guidance
Prior authorization is often required
Willow is the only no-membership semaglutide provider that coordinates GLP-1 and HRT care together
At 2.5 mg, receptor activation is mild
The medication is administered as a once-weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm